Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
By F. Kabbinavar, J. Hambleton, R. Mass, H. Hurwitz, E. Bergsland, S. Sarkar. Journal of Clinical Oncology, 2005
703 citations recorded by the source corpus.
Subfields: Biotechnology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/a84632b33324c1330c007f2c5c1764704b3ee510
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. Grothey
- M. Sugrue
- D. Sargent
- D. Purdie
- W. Dong
- E. Hedrick
- M. Kozloff
Citations in the corpus
- Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). (2008, methodology): “Given that the BRiTE study included a less selective patient population than RCTs (eg, a higher proportion of patients who were elderly and a higher proportion of patients with poor prognostic factors), the OS estimate was longer than expected.(2,3,5,8,12-14) The apparent dissociation of PFS and OS ”